Medicated Skin Care in Macedonia
US$ 990.00
... and Kantarion, from Alkaloid and Fitopharm respectively. Euromonitor International's Medicated Skin Care in Macedonia report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
23 pages
Medicated Skin Care in Finland
US$ 990.00
... the gloomier outlook for the Finnish economy. Euromonitor International's Medicated Skin Care in Finland report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
34 pages
Ear Care in Slovakia
US$ 990.00
... years, awareness of ear care consistently increased, as consumers started to pay more attention to and look after their ears properly, as they care for other parts of their body. In 2011, ear care grew by 1% in current value terms. Euromonitor International's Ear Care in Slovakia report offers ...
May 2012
20 pages
Medicated Skin Care in Cameroon
US$ 990.00
... needing medicated skincare or teenagers with acne treatments or other skin treatments. The category experienced 5% current value growth in 2011. Euromonitor International's Medicated Skin Care in Cameroon report ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
19 pages
Medicated Skin Care in Poland
US$ 990.00
... special attention to the health benefits of self-medication and the high efficacy of available... Euromonitor International's Medicated Skin Care in Poland report offers a comprehensive guide to the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
32 pages
Medicated Skin Care in Slovakia
US$ 990.00
... for various skin infections. Slovak consumers are very sensitive about their skin problems and pay more attention to prevention. Therefore, medicated skin care is becoming more popular each year. In 2011, it grew by 2% with overall current value sales reaching EUR13.3 million. Euromonitor International's Medicated Skin Care in Slovakia report ...
May 2012
27 pages
The Art of Positioning Dietary Supplements
US$ 2,000.00
... regulatory activity. An effective message regarding health benefits, and the localisation of products will advance sales. Euromonitor International’s The Art of Positioning Dietary Supplements global briefing examines the size, growth trends and potential opportunities in the Consumer Health market. The ...
May 2012
60 pages
Medicated Skin Care in Spain
US$ 990.00
... economic conditions experienced in Spain are clearly affecting sales of medicated skin care as they did the rest of Spanish consumer health. Moreover in Spain, in 2011 the number ... of unemployment distress in Spain, as although one member may be unemployed the economic needs of the family unit... Euromonitor International's Medicated Skin Care in Spain report offers a comprehensive ...
May 2012
38 pages
Merck KGaA in Consumer Health (World)
US$ 572.00
Merck KGaA is a global top 20 producer of consumer health products. Despite relatively consistent revenue growth, the company has struggled to consistently gain share of the global consumer health ... . Euromonitor International’s Merck KGaA in Consumer Health (World) Company Profile offers detailed strategic analysis of the company’s business, examining its performance in the Consumer Health industry. The ...
May 2012
34 pages
Medicated Skin Care in Colombia
US$ 990.00
... . Haemorrhoid treatments increased by 7% in current value terms in 2011. Euromonitor International's Medicated Skin Care in Colombia report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
35 pages
Medicated Skin Care in Brazil
US$ 990.00
... experienced during the review period can largely be... Euromonitor International's Medicated Skin Care in Brazil report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
46 pages
Medicated Skin Care in Bosnia-Herzegovina
US$ 990.00
... as a whole, medicated skin care’s performance in 2011 was quite similar at 5% in current value terms. Medicated skin care recovered in 2011 from a decline in 2010 caused by the recession. Skin care problems ... , which means that demand for medicated skin care products is quite elastic during periods of economic instability. Euromonitor International's Medicated Skin Care in Bosnia-Herzegovina report offers a comprehensive guide ...
May 2012
22 pages
CIPLA - Nothing New – As Expected
US$ 140.00
... ‘rationalization’ of various partnerships in different geographies. Launch of Dymista and Vancomycin by Cipla’s partners in US too may not fetch any meaningful upside in the ... near term. We reiterate our Market Perform on Cipla but change our target price to `341 as we rollover to FY13 ...
May 2012
7 pages
REGENERON - Diversified Pipeline can Buffer the Setback
US$ 140.00
Despite the setback in the pipeline – negative recommendation from FDA advisory committee on ... franchise should be able to buffer some setbacks in the pipeline. The FDA advisory panel voted 11-0 against approval of the ... , released on May 14, 2012 on REGN, titled “Diversified Pipeline can Buffer the Setback”.
May 2012
6 pages
CADILA HEALTHCARE - Nearing Inflection Point
US$ 140.00
Cadila’s Q4 FY12 result was much higher than our estimates owing to ... declined by 4.5% due to forex loss. FY12 remained a year of consolidation after Cadila acquired Nesher, Bremer and Biochem. Going forward, the company ...
May 2012
8 pages
Medicated Skin Care in Ukraine
US$ 990.00
... -medicate and tend to buy advertised products (usually more expensive than generics), which also contributes to value over volume... Euromonitor International's Medicated Skin Care in Ukraine ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
37 pages
Ear Care in Guatemala
US$ 990.00
... to buy OTC ear care. Instead, they will most likely refer to a health specialist who will then prescribe a medicine. As a whole, ear care shows strong growth mainly as a result of a small actual market size, but it lacks real dynamism. Euromonitor International's Ear Care in Guatemala report offers ...
May 2012
19 pages
Medicated Skin Care in Guatemala
US$ 990.00
... current value sales. Medicated skin care consists of several types of products, but it is more highly concentrated in antifungals. Euromonitor International's Medicated Skin Care in Guatemala report offers a comprehensive guide ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
23 pages
Medicated Skin Care in Dominican Republic
US$ 990.00
... inside medicated skin care are cold sore treatments with a 9% and similar increases for hair loss and nappy rash treatments. Euromonitor International's Medicated Skin Care in Dominican Republic ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
23 pages
Medicated Skin Care in Latvia
US$ 990.00
Medicated skin care had overall growth in 2011 based on improving economic situation in Latvia. Growth was achieved as consumers became more willing to spend on skin disease treatment ... forms of skin problems. In addition, lower number of discount promotions compared to 2010 was another factor that affected growth. Euromonitor International's Medicated Skin Care in Latvia report ...
May 2012
24 pages
Medicated Skin Care in Malaysia
US$ 990.00
... image or topical antiseptics/germicidals to ease any skin issues encountered during travelling. Euromonitor International's Medicated Skin Care in Malaysia report offers a comprehensive guide to the size ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
May 2012
27 pages
Medicated Skin Care in South Africa
US$ 990.00
Medicated skin care is characterised by intensive competition; such a trend restricted entry for new entrants during 2011. Skin care is very competitive and consumers really need to be convinced of the effectiveness of a product as well as its affordability. Euromonitor International's Medicated Skin Care in South Africa report offers ...
May 2012
32 pages
INCYTE: JAKAFI / JAKAVI to Drive Sustainable Profitability
US$ 140.00
Incyte (INCY) reported net revenues of $19.3m of the only approved drug for Myelofribrosis (MF), JAKAFI / JAKAVI (ruxolitinib, JAK 1/2 inhibitor, PhII/III in PV/ET; partnered with Novartis for ... , please read our report released on May 2, 2012 on INCY, titled “JAKAFI / JAKAVI to Drive Sustainable Profitability”
May 2012
3 pages
Competitor Analysis: Janus Kinase (JAK) Inhibitors
US$ 394.00
... Report about new developments in the pipeline of inhibitors of the janus-associated kinase (JAK) provides a competitor evaluation in the field of active R&D projects from ... have been identified: JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2). JAK3 has attracted much attention as an anti-inflammatory drug target ...
May 2012
44 pages
India IVF Treatment Market Analysis
US$ 500.00
... , pelvic inflammatory diseases, etc. Today, arrays of treatment options to treat infertility are readily available in India. These include medications for ovulation induction ... IUI, IVF, and ICSI (intra cytoplasmic sperm injection). India has become one of the favored destinations for infertility treatments such as IVF due to several ...
May 2012
40 pages
Medicated Skin Care in Taiwan
US$ 990.00
... 2011, medicated skin care grew 4% in current value terms to reach NT$2.5 billion. Taiwan has a warm and humid climate, which has been the ... in Taiwan. Dermatitis, dandruff, tinea unguium, athlete’s foot, candidiasis, skin allergy and dyshidrosis are seven very common skin conditions in Taiwan. Euromonitor International's Medicated Skin Care in Taiwan report ...
April 2012
28 pages
Osteoporosis Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following Therapeutic Classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, ... 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 49 companies including many key and niche ...
April 2012
455 pages
China Healthcare Market Forecast to 2015
US$ 1,000.00
With the advancement of infrastructure, Chinese Healthcare Industry is entering into a new era of development. A large population-base along with increasing aging population, and continuously growing...
April 2012
135 pages
Global Trauma Market Report: 2012 Edition
US$ 800.00
The worldwide trauma market has experienced significant growth in the past and the market has considerable growth opportunity in the near future as the worldwide demand for trauma products is increasi...
April 2012
43 pages
Managing Investigator Initiated Research
US$ 595.00
... , and a fresh perspective on stakeholders’ roles and responsibilities. Report Overview Managing Investigator-Initiated Research This comprehensive report brings together industry data, exclusive ... end-to-end IIR programme management Who Would Benefit From This Report? Managers and Executives with responsibilities in: Investigator-initiated research (IIR) programmes Branding ...
April 2012
74 pages
Nutritional Supplements Market Report: 2012 Edition
US$ 800.00
... other countries like France and Denmark. The report provides an analysis of the global nutritional supplements market. It also discusses the major trends, ... growth drivers and challenges for the market. The report presents the ...
April 2012
40 pages
Medicated Skin Care in Mexico
US$ 990.00
... , are capitalising on this epidemic, launching several new... Euromonitor International's Medicated Skin Care in Mexico report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
April 2012
49 pages
Medicated Skin Care in Venezuela
US$ 990.00
... . These categories benefit from large-scale advertising... Euromonitor International's Medicated Skin Care in Venezuela report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
April 2012
30 pages
Medicated Skin Care in Japan
US$ 990.00
... level of stress is rising and an associated reduction in the... Euromonitor International's Medicated Skin Care in Japan report offers a comprehensive guide to the size and shape of the ... Treatments, Haemorrhoid Treatments, Hair Loss Treatments, Medicated Shampoos, Nappy (Diaper) Rash Treatments, Paediatric Medicated Skin Care, Topical Allergy Remedies/Antihistamines, Topical Antifungals ...
April 2012
48 pages
CELGENE – Revlimid Sales Disappoints, but Long Term Prospects Intact!
US$ 90.00
Though Q1’12 earnings were disappointing (flat growth of Revlimid), we expect Celgene (CELG) should able to meet its FY12 guidance (Total rev.: $5.4-$5.6b ... read our report released on 27th April, 2012 on CELG titled, “Revlimid Sales Disappoints, but Long Term Prospects Intact!”
April 2012
4 pages
